Current and emerging treatment strategies for Duchenne muscular dystrophy

Jean K Mah
Department of Pediatrics and Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

Abstract: Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy in childhood. It is caused by mutations of the DMD gene, leading to progressive muscle weakness, loss of independent ambulation by early teens, and premature death due to cardiopulmonary complications. The diagnosis can usually be made after careful review of the history and examination of affected boys presenting with developmental delay, proximal weakness, and elevated serum creatine kinase, plus confirmation by muscle biopsy or genetic testing. Precise characterization of the DMD mutation is important for genetic counseling and individualized treatment. Current standard of care includes the use of corticosteroids to prolong ambulation and to delay the onset of secondary complications. Early use of cardioprotective agents, noninvasive positive pressure ventilation, and other supportive strategies has improved the life expectancy and health-related quality of life for many young adults with DMD. New emerging treatment includes viral-mediated microdystrophin gene replacement, exon skipping to restore the reading frame, and nonsense suppression therapy to allow translation and production of a modified dystrophin protein. Other potential therapeutic targets involve upregulation of compensatory proteins, reduction of the inflammatory cascade, and enhancement of muscle regeneration. So far, data from DMD clinical trials have shown limited success in delaying disease progression; unforeseen obstacles included immune response against the generated mini-dystrophin, inconsistent evidence of dystrophin production in muscle biopsies, and failure to demonstrate a significant improvement in the primary outcome measure, as defined by the 6-minute walk test in some studies. The long-term safety and efficacy of emerging treatments will depend on the selection of appropriate clinical end points and sensitive biomarkers to detect meaningful changes in disease progression. Correction of the underlying mutations using new gene-editing technologies and corticosteroid analogs with better safety profiles offers renewed hope for many individuals with DMD and their families.

Keywords: Duchenne muscular dystrophy, emerging treatment, standard of care, review

Introduction – case illustration

A 3-year-old boy is referred for evaluation of developmental delay. He was born after an unremarkable pregnancy at term, with no complications. His development was normal during the first year. Although he is generally healthy and has good muscle bulk, he did not walk until after his second birthday. He is shy and he currently speaks in single words only. His examination is normal apart from calf hypertrophy. His parents want to know more about the diagnosis and available treatment options.
Background on Duchenne muscular dystrophy

Duchenne muscular dystrophy (DMD) is a genetic muscle disorder that affects one per 3,500–5,000 live-born males; it is the most common type of muscular dystrophy in childhood. It is caused by mutations of the DMD gene, located on chromosome Xp21, which encodes for dystrophin, a 427 kDa protein that is expressed at the muscle sarcolemma. The absence of dystrophin destabilizes the muscle membrane, leading to the clinical features of motor developmental delay, calf hypertrophy, joint contractures, and progressive muscle weakness in affected boys, with markedly elevated serum CK that reflects ongoing muscle damage. In addition, boys with DMD may have a variable degree of speech delay, learning disability, and/or cognitive impairment. Progressive muscle degeneration eventually leads to loss of independent ambulation by early adolescence, scoliosis, cardiomyopathy, respiratory insufficiency, and reduced life expectancy, with death occurring before the third or fourth decade of life due to cardiorespiratory complications, according to recent DMD natural history studies.

The DMD gene is one of the largest known human genes. It contains 79 exons, which include an actin-binding domain at the N-terminus, 24 spectrin-like repeat units, a cysteine-rich dystroglycan binding site, and a C-terminal domain. The extremely large size of the gene contributes to a complex mutational spectrum, with >7,000 different mutations and a high spontaneous mutation rate. Approximately two-thirds of cases are maternally inherited; the remaining one-third occurs as a result of spontaneous mutations. Large (one or more exons) deletions account for approximately two-thirds of all DMD mutations; the rest are due to duplications and small deletions, insertions, point mutations, or splicing mutations. The severe phenotype associated with DMD is most often caused by out-of-frame mutations, with complete loss of the dystrophin protein.

In-frame mutations that allow for the synthesis of an internally truncated but partially functional protein are associated with a milder and more variable phenotype known as Becker muscular dystrophy or X-linked dilated cardiomyopathy; exceptions to the reading frame hypothesis occur in <10% of all DMD mutations. Disease severity is also affected by other genetic modifiers distinct from the DMD gene, including single nucleotide polymorphism of the latent transforming growth factor-beta (TGF-β) binding protein 4 (LBP4) gene and osteopontin, encoded by the secreted phosphoprotein 1 (SPP1) gene; both genes appear to influence disease progression in DMD by modifying the age at loss of independent ambulation, the age at onset of dilated cardiomyopathy, and the clinical response to corticosteroid treatment.

Dystrophin is an integral part of the dystrophin-associated glycoprotein complex. It is in close association with other cytoskeletal proteins, including F-actin via its N-terminus and part of the rod domain; it also binds to dystroglycan via its cysteine-rich domain and to syntrophin via the C-terminal domain. Thus, dystrophin provides structural stability to the skeletal muscle by connecting the sarcolemma and the basal lamina of the extracellular matrix to the inner cytoskeleton. It is also essential for cell survival via its transmembrane signaling function and modulation of vasomotor response to physical activity. Three isoforms of dystrophin are derived from independent promoters in the brain, retina, and Purkinje cerebellar neurons; mutations in these tissue specific isoforms of dystrophin likely contribute to the extramuscular manifestations of DMD, including cognitive, behavioral, and learning difficulties.

Loss of dystrophin as a result of DMD gene mutations disrupts the dystrophin glycoprotein complex, leading to increased muscle membrane fragility. A cascade of events including influx of calcium into the sarcoplasm, activation of proteases and proinflammatory cytokines, and mitochondrial dysfunction results in progressive muscle degeneration. In addition, displacement of neuronal nitric oxide synthase contributes to tissue ischemia, increased oxidative stress, and reparative failure. Disease progression is characterized by increasing muscle necrosis, fibrosis, and fatty tissue replacement and a greater degree of fiber size variation seen in subsequent muscle biopsies.

Making a diagnosis of DMD

The diagnosis of DMD can usually be made after a careful review of the clinical history, physical examination, and confirmation by additional investigations, including muscle biopsy and/or molecular genetic testing. A positive family history of DMD is not required, as approximately one-third of cases may occur as a result of spontaneous mutation. The presence of motor developmental delay with or without speech delay and muscle hypertrophy in a young boy should trigger the order of serum CK as an initial diagnostic screen for DMD, especially if the child also has signs of proximal muscle weakness, manifesting as an abnormal waddling gait, or a positive Gowers’ sign (Figure 1). As shown in the case illustration earlier, the muscle enzymes as measured by serum CK are usually markedly elevated. Raised muscle enzymes in DMD also contribute...
to persistently high serum alanine and aspartate transaminase levels; in some cases, the diagnosis may be delayed due to initial investigations for suspected hepatic dysfunction.

Genetic testing for DMD mutations includes multiplex polymerase chain reaction focusing on the most commonly deleted regions of the gene or other assays that interrogate all 79 exons, such as multiplex ligation-dependent probe amplification (MLPA) or comparative genomic hybridization (CGH) microarray. If these diagnostic tests fail to identify the presence of a disease-causing deletion or duplication, complete gene sequencing is required to define the precise mutational event. A muscle biopsy can also be obtained for dystrophin immunostaining and extraction of RNA to produce complementary DNA and confirm a dystrophin mutation. The muscle biopsy typically shows a dystrophic process with ongoing muscle degeneration and regeneration; dystrophin immunostaining is usually absent or markedly reduced, except in rare revertant fibers. Using currently available diagnostic methods, it is possible to identify the mutations and confirm the clinical phenotypes in nearly all patients with dystrophinopathy.

Supportive treatment for DMD

Identification of a specific mutation is important for accurate diagnosis, prognosis, and individualized treatment for affected boys with DMD, as well as genetic counseling for their families. Beyond realizing the severity of the diagnosis, parents live with uncertainty in anticipation of future losses and limitations that their children will experience, and anxiety as to how their children may react to those losses. For most parents, the demand of caring for their child with neuromuscular disease was disruptive to family life; the needs of the siblings, the spouse, and the primary caregiver tended to become secondary priorities. The stress caused by the cognitive, behavioral, and other psychosocial challenges related to DMD can sometimes exceed those associated with the physical aspects of the disease. Increased burden of care and emotional distress are also common among caregivers of adults with DMD. These realities underscore the need for assessment and support of the entire family. Family-centered care, timely referrals, and appropriate community support can help parents to become experts on their child’s diagnosis and normalize their daily care routine (Table 1). Mothers who are confirmed carriers of dystrophin mutations will also require periodic health surveillance for possible cardiomyopathy, myalgia, and/or proximal muscle weakness.

There is presently no cure for DMD. Current treatment strategies focus on optimizing growth and development, promoting well-balanced diet, participating in physical and recreational activity, and delaying the onset of secondary complications through ongoing medical and psychosocial support. Supportive interventions including timely treatment with corticosteroids, early afterload reduction for cardiomyopathy, aggressive management of heart failure, noninvasive positive pressure ventilation, and effective airway clearance strategies have contributed to prolonged...
survival of individuals with DMD. The mean age of death from DMD increased from 14.4 years in the 1960s to 25.3 years in the 1990s, with corresponding improvement in affected individuals’ health-related quality of life.\textsuperscript{36–38}

### Table 1 Current supportive strategies for DMD

<table>
<thead>
<tr>
<th>Key stages and strategies</th>
<th>Early to late ambulatory stage (4–9 years old)</th>
<th>Early nonambulatory stage (10–16 years old)</th>
<th>Late nonambulatory stage (&gt;16 years old)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Family knowledge:</td>
<td>Discuss: DMD natural history</td>
<td>Discuss: Review previous topics</td>
<td>Discuss: Review previous topics</td>
</tr>
<tr>
<td>Identify family’s needs,</td>
<td>Role of corticosteroids</td>
<td>Nutrition, scoliosis, cardiac, respiratory</td>
<td>Home care</td>
</tr>
<tr>
<td>and priorities on an ongoing</td>
<td>Genetic counseling</td>
<td>issues, and corticosteroids-related side effects</td>
<td>Cardiac treatment</td>
</tr>
<tr>
<td>basis</td>
<td>Carrier testing if indicated</td>
<td>Management of nocturnal hypoventilation and cardiomyopathy if present</td>
<td>Nutritional support</td>
</tr>
<tr>
<td>Provide information that</td>
<td>Provide written material, websites, and peer support information</td>
<td>School and social support</td>
<td>Options for long-term ventilation support</td>
</tr>
<tr>
<td>matches the family’s needs</td>
<td>Participation in DMD research</td>
<td>Respite and financial needs</td>
<td>Transition to adult services</td>
</tr>
<tr>
<td>Facilitate family-to-family</td>
<td>Parent project website</td>
<td>Adolescent quality of life</td>
<td>Advance care directive</td>
</tr>
<tr>
<td>support</td>
<td>MDA</td>
<td></td>
<td>Medical consultations:</td>
</tr>
<tr>
<td>Professional support:</td>
<td>Medical consultations:</td>
<td></td>
<td>As before, plus:</td>
</tr>
<tr>
<td>Develop services that are</td>
<td>Genetics</td>
<td></td>
<td>Palliative care</td>
</tr>
<tr>
<td>flexible to the needs of</td>
<td>Respirology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>individual families</td>
<td>Orthopedics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provide service coordination</td>
<td>Cardiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>and integration within and</td>
<td>Neurology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>between sectors</td>
<td>Pediatrics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allied health support:</td>
<td>Physiaty</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinics, Dietitian</td>
<td>Ophthalmology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Professional support:</td>
<td>Medical consultations:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical consultations:</td>
<td>Genetics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provide high-quality general</td>
<td>Respiratory</td>
<td></td>
<td></td>
</tr>
<tr>
<td>and illness-specific</td>
<td>Orthopedics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>information</td>
<td>Cardiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Establish opportunities for</td>
<td>Neurology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>family involvement in</td>
<td>Pediatrics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>decision-making at all levels</td>
<td>Physiatry</td>
<td></td>
<td></td>
</tr>
<tr>
<td>of the organization</td>
<td>Ophthalmology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical/laboratory monitoring</td>
<td>Allied health support:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Create family-friendly physical</td>
<td>MDA community liaison</td>
<td></td>
<td></td>
</tr>
<tr>
<td>environments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight management</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical/laboratory monitoring</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight, height</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood pressure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muscle function testing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECG, echocardiogram</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary function testing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spine X-ray</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wrist X-ray for bone age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone densitometry scan</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25-hydroxyvitamin D level</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


**Abbreviations:** DMD, Duchenne muscular dystrophy; MDA, muscular dystrophy association; ACE, angiotensin-converting enzyme; ECG, electrocardiography.

### Standard of care for DMD

Recent publications from leading experts have provided comprehensive guidelines on the diagnosis and multidisciplinary management of DMD, including the use of...
corticosteroids.\textsuperscript{3,33,39,40} Historically, corticosteroids offered benefit to boys with DMD by stabilizing muscle strength and function,\textsuperscript{41,42} prolonging independent ambulation,\textsuperscript{43,44} and delaying the progression of scoliosis\textsuperscript{45} and cardiomyopathy.\textsuperscript{46} Continued treatment after loss of independent ambulation has also been shown to be beneficial.\textsuperscript{47,48} On the basis of available literature and clinical experience, current clinical practice guidelines strongly endorse the consideration of corticosteroid therapy for all DMD patients, starting at the early ambulatory stage of the disease.\textsuperscript{3,49} Daily oral prednisone (0.75 mg/kg) or deflazacort (0.9 mg/kg) is generally recommended as a disease-modifying treatment for DMD; intermittent steroids dosing schedule (10 days on/10 days off or high dose weekends only) are less commonly prescribed.\textsuperscript{50} Prednisone and deflazacort are currently being studied in a head-to-head fashion as part of the FOR-DMD (NCT01603407) clinical trial; the results will hopefully determine the optimal corticosteroid regimen for DMD.

Common steroid-related side effects include short stature, obesity, cataracts, and skeletal fractures.\textsuperscript{51} In particular, approximately one-third of boys with DMD may develop vertebral compression fractures due to long-term corticosteroid use, progressive muscle weakness, impaired vitamin D and calcium absorption, and immobilization. Regular physical activity, calcium-enriched diet, optimization of vitamin D, and periodic assessments including lateral spine X-ray and bone density by dual energy X-ray absorptiometry scan are recommended as part of bone health management.\textsuperscript{35} Bisphosphonates are generally reserved for those with symptomatic vertebral compression and/or recurrent fragility fractures in the extremity, in association with persistent or multiple bone health risk factors;\textsuperscript{52} however, the long-term efficacy of bisphosphonate therapy for boys with DMD remains limited.\textsuperscript{53,54} Alternative treatments including denosumab and recombinant parathyroid hormone have not been formally evaluated in DMD.\textsuperscript{54}

Cardiac complications are common in DMD, including myocardial necrosis, conduction defects, and/or arrhythmias.\textsuperscript{55,56} Progressive cardiomyopathy is one of the leading causes of mortality in DMD.\textsuperscript{36,57} Common electrocardiography (ECG) abnormalities include sinus tachycardia, tall R waves in V1, deep Q waves in the inferolateral leads, ST depression, prolonged QT interval, and increased QT dispersion.\textsuperscript{58} Echocardiographic evidence of structural heart disease in DMD patients includes left ventricular hypertrophy, regional wall motion abnormalities, dilation of the cardiac chambers, valvular abnormalities, and left ventricular systolic dysfunction.\textsuperscript{59,60} Despite the high prevalence of cardiac disease, most affected individuals are asymptomatic due to their low physical capability,\textsuperscript{61} the diagnosis and treatment of DMD-related cardiomyopathy were often delayed.\textsuperscript{62} According to the 2010 DMD guidelines, baseline assessment including ECG and echocardiogram should be performed at diagnosis, with reassessments at least every 2 years and then annually after 10 years of age.\textsuperscript{35} However, echocardiograms may be technically difficult in DMD due to the development of progressive scoliosis, chest wall deformities, and respiratory insufficiency, thus limiting the utility of echocardiograms among patients with more advanced stages of the disease.

Increasingly, cardiac magnetic resonance imaging (MRI) has been used for the surveillance of myocardial dysfunction in DMD, especially in combination with gadolinium.\textsuperscript{63} Using late gadolinium enhancement, cardiac MRI may detect early myocardial fibrosis, in the absence of any overt echocardiographic abnormalities;\textsuperscript{64} however, young children (especially <6 years old) or those with significant cognitive or behavioral issues may not be able to tolerate the procedure without sedation. Early use of cardioprotective treatment including angiotensin-converting enzyme (ACE) inhibitors or beta-blocker may help delay the progression of cardiomyopathy.\textsuperscript{35,58} The addition of eplerenone to ACE inhibitors can also attenuate the decline in left ventricular systolic function.\textsuperscript{65} According to a recent DMD working group, new cardiac guidelines will soon be available to address the expanded use of cardiac MRI, the use of myocardial strain analysis and other advanced echocardiographic imaging techniques, and the need for early initiation of anti-heart failure regimen for the treatment of DMD-related cardiomyopathy.\textsuperscript{65}

Individuals with DMD are also at increasing risk of respiratory complications due to progressive decline in respiratory muscle function.\textsuperscript{66,67} Signs of respiratory insufficiency include ineffective cough, recurrent chest infection, nocturnal hypoventilation, sleep disordered breathing, and eventually daytime respiratory failure.\textsuperscript{36,57} Regular pulmonary function testing is needed to monitor for early signs of respiratory insufficiency and to optimize treatment.\textsuperscript{35} The initial treatment for nocturnal hypoventilation in DMD patients includes noninvasive positive pressure ventilation by nasal prongs or face mask to improve sleep quality, decrease daytime sleepiness, enhance gas exchange, and delay the decline in the pulmonary function.\textsuperscript{68} Additional supportive strategies include chest physiotherapy, mechanical insufflation–exsufflation, and/or lung volume recruitment exercises to improve lung compliance and prevent atelectasis.\textsuperscript{69,70} The combination of noninvasive positive pressure ventilation, assisted airway
Therapeutic strategies for DMD

Recent scientific advances have led to new disease-modifying treatments for many neuromuscular diseases including DMD.74–76 Identification of coordination centers and patients eligible for specific DMD trials has been greatly facilitated by the establishment of TREAT-NMD and other international DMD disease registries.15 Regularly updated information about DMD clinical trials is available at https://www.ClinicalTrials.gov. A significant proportion of the active studies are enrolling participants by invitation only; as well, many of the studies listed are either Phase I safety or smaller Phase II pilot studies, with a fewer number of Phase III double-blind randomized trials. The main therapeutic strategies include, 1) gene replacement or other genetic therapies linked to specific mutations to restore dystrophin production;77–79 2) membrane stabilization and/or upregulation of compensatory proteins;80,81 and 3) reduction of the inflammatory cascade and/or enhancement of muscle regeneration (Table 2).82,83 Specific examples of emerging therapeutic strategies for DMD, including exon skipping and nonsense mutation suppression therapies, are briefly summarized in the genetic therapies section.

Table 2 Emerging therapies for DMD

<table>
<thead>
<tr>
<th>Gene replacement therapies</th>
<th>Other genetic therapies</th>
</tr>
</thead>
<tbody>
<tr>
<td>rAAV2.5-CMV-Mini-dystrophy</td>
<td>Nonsense suppression</td>
</tr>
<tr>
<td>rAAVrh74.MCK Mini-dystrophy</td>
<td>Gentamicin</td>
</tr>
<tr>
<td>rAAV1.CMV.huFollistatin344</td>
<td>Ataluren (Translarna)</td>
</tr>
<tr>
<td>Gene replacement therapies</td>
<td>NPC-14 (arbekacin sulfate)</td>
</tr>
<tr>
<td>Other genetic therapies</td>
<td></td>
</tr>
<tr>
<td>Exon skipping</td>
<td></td>
</tr>
<tr>
<td>Exon 53</td>
<td></td>
</tr>
<tr>
<td>SRP4053 (Serapta)</td>
<td></td>
</tr>
<tr>
<td>PRO053 (Proensa)</td>
<td></td>
</tr>
<tr>
<td>NS-065/NCNP-01</td>
<td></td>
</tr>
<tr>
<td>Exon 51</td>
<td></td>
</tr>
<tr>
<td>AVI-4658/eteplirsen</td>
<td></td>
</tr>
<tr>
<td>GSK2402968/drisapersen</td>
<td></td>
</tr>
<tr>
<td>Exon 45</td>
<td></td>
</tr>
<tr>
<td>DS-5141b</td>
<td></td>
</tr>
<tr>
<td>PRO045</td>
<td></td>
</tr>
<tr>
<td>SRP4045</td>
<td></td>
</tr>
<tr>
<td>Exon 44</td>
<td></td>
</tr>
<tr>
<td>PRO044</td>
<td></td>
</tr>
<tr>
<td>Cell therapy using muscle precursor cells or stem cells</td>
<td></td>
</tr>
<tr>
<td>Myoblasts transfer</td>
<td></td>
</tr>
<tr>
<td>Mesangioblasts transplantation</td>
<td></td>
</tr>
<tr>
<td>Umbilical cord based allogenic mesenchymal stem cells</td>
<td></td>
</tr>
<tr>
<td>Bone marrow autologous and mononuclear stem cells</td>
<td></td>
</tr>
<tr>
<td>Membrane stabilization and upregulation of cytoskeletal proteins</td>
<td></td>
</tr>
<tr>
<td>Urotropin upregulation: SMT C1100</td>
<td></td>
</tr>
<tr>
<td>Treatment of secondary cascades</td>
<td></td>
</tr>
<tr>
<td>Anti-inflammatory drugs</td>
<td></td>
</tr>
<tr>
<td>Givinostat (HDAC inhibitor)</td>
<td></td>
</tr>
<tr>
<td>CAT-1004 (NF-xB inhibitor)</td>
<td></td>
</tr>
<tr>
<td>Flavocoxid</td>
<td></td>
</tr>
<tr>
<td>TAS-205 (PDGD2 synthase inhibitor)</td>
<td></td>
</tr>
<tr>
<td>Others: idebenone, pentoxifylline, coenzyme Q10, oxatamide</td>
<td></td>
</tr>
<tr>
<td>Antifibrotic drugs/transforming growth factor beta (TGF-β) inhibitors</td>
<td></td>
</tr>
<tr>
<td>Losartan and lisinopril</td>
<td></td>
</tr>
<tr>
<td>HT-100 (halofuginone)</td>
<td></td>
</tr>
<tr>
<td>FG-3019 (monoclonal antibody to CTGF)</td>
<td></td>
</tr>
<tr>
<td>Muscle regeneration</td>
<td></td>
</tr>
<tr>
<td>Myostatin inhibitors: ACE-031, PF-06252616; BMS-986099</td>
<td></td>
</tr>
<tr>
<td>Insulin growth factor (IGF-1)</td>
<td></td>
</tr>
<tr>
<td>Treatment of muscle ischemia</td>
<td></td>
</tr>
<tr>
<td>Phosphodiesterase 5 (PDE5) inhibitors: tadalafil and sildenafil</td>
<td></td>
</tr>
<tr>
<td>VEGF</td>
<td></td>
</tr>
</tbody>
</table>

Notes: *Active or ongoing clinical trials, accessed on February 18, 2016 from www.clinicaltrials.gov. **Abbreviations: DMD, Duchenne muscular dystrophy; NF-xB, nuclear factor-kappa B; TGF-β, transforming growth factor beta; CTGF, connective tissue growth factor; ACE, angiotensin-converting enzyme; IGF, insulin growth factor; PDE5, phosphodiesterase 5; VEGF, vascular endothelial growth factor.

Genetic therapies

Dystrophin gene replacement using virus vectors

Previous attempts to develop gene therapy for DMD have been complicated by the enormous size of the dystrophin gene. This was subsequently addressed by deleting selective regions of the dystrophin protein, leading to the generation of functional
mini- and microdystrophins. Injection of adeno-associated viruses carrying microdystrophins into dystrophic canine model of DMD results in a striking improvement in the muscle histopathology. However, earlier attempts in six boys with DMD due to frameshift mutations failed to achieve successful transgene expression, in part due to an unexpected primed T-cell-mediated immune response to the generated mini-dystrophin seen in two of the participants. Additional clinical trials using recombinant adeno-associated viruses and more efficient vector delivery system to replace defective genes in DMD are currently in progress.

**Exon skipping**

Exon skipping uses synthetic antisense oligonucleotide sequences to correct specific dystrophin gene mutations. It does so by inducing specific exons skipping during pre-messenger RNA (pre-mRNA) splicing of the dystrophin gene, resulting in restoration of the reading frame and partial production of an internally truncated protein, similar to the dystrophin protein expression seen in Becker muscular dystrophy. Antisense therapies that induce single or multiple exon skipping could potentially be helpful for the majority of dystrophin mutations.

An earlier Phase I clinical trial of four boys with DMD using PRO051, a 2′-O-methyl-phosphorothioate oligoribonucleotide designed to skip exon 51 in dystrophin pre-mRNA, showed partial (17%–35%) restoration of dystrophin after a single intramuscular injection into the tibialis anterior. This was followed by a Phase II study including weekly subcutaneous injections of PRO051, also known as drisapersen, up to 6 mg/kg/dose into 12 young DMD boys with a mean age of 9.2 years (range 5–13 years). In addition to injection site reactions, drisapersen was associated with transient elevation of o1-microglobulinaemia and variable proteinuria; a slight increase in dystrophin expression and a modest improvement in the mean 6-minute walk test (6MWT) distance of 35.2 m (SD 28.7 m) were seen after a 3-month open-label extension treatment. Furthermore, a single subcutaneous injection of drisapersen at escalating doses for 20 nonambulatory boys aged 9–12 years with DMD was well tolerated, aside from transient proteinuria, fever, and acute inflammatory reactions seen in three participants given the 9 mg/kg dose. However, a larger Phase III clinical trial involving 186 boys with DMD (NCT01254019) failed to show a significant difference in the 6MWT among participants on drisapersen versus placebo. In a subsequent Phase II study involving a younger (mean age of 7.3 years, range 5–11 years) cohort of 53 patients with DMD, boys receiving continuous drisapersen weekly for 25 weeks demonstrated a slight improvement in the 6MWT and increased expression of dystrophin; however, there was no significant difference in the 6WMT at week 49. Furthermore, results of formal muscle strength and other timed function tests did not differ between either continuous or intermittent drisapersen regimen versus placebo. Further data from the open-label extension study of drisapersen (NCT02636686) is pending.

Eteplirsen (AVI-4658) is a phosphoramidate morpholino oligomer designed specifically for exon 51 skipping. In a subsequent double-blind placebo-controlled trial involving 12 participants (age 7–12 years) for 24 weeks followed by an open-label extension study of eteplirsen at either 30 mg/kg/wk or 50 mg/kg/wk, Mendell et al found encouraging results in a subset (n=10) of participants, with significant improvement in walking ability and stabilization in their clinical function, and histological evidence of de novo dystrophin production and restoration of the dystrophin-associated protein complex in the muscle biopsies. Two older twin boys lost ambulation due to rapid disease progression, and they were excluded from the modified intention-to-treat analysis. No significant adverse effects were noted after weekly treatment for >3 years following the open-label extension study. The clinical benefits of eteplirsen for DMD will be determined as part of a larger confirmation study that is currently underway (PROMOVI, NCT0225552). Other exon skipping trials involving exons 44, 45, 53, and multiple exon skipping are planned.

**Nonsense suppression therapy**

Approximately 10%–15% of DMD is caused by point mutations leading to a premature stop codon. Premature stop codons are nucleotide triplets within mRNA that signal the termination of protein translation by binding release factors and causing the ribosomal subunits to disassociate and release the shortened amino acid chain. This usually results in a loss of the functional protein, as critical parts of the amino acid chain are missing. Aminoglycosides and other nonsense mutation suppression agents bind to the ribosomal RNA subunits and impair the recognition of premature stop codons, thus allowing translation and production of a modified dystrophin protein. Earlier treatment trials with gentamicin showed mixed results, with additional caution regarding its long-term use due to potential renal- and oto-toxicity. Ataluren (also known as Translarna) is an orally bioavailable drug designed to overcome premature nonsense mutations. Early studies of ataluren showed that it was generally safe and well tolerated. Among 174 boys with DMD due to confirmed premature stop codon mutations, a double-blind placebo-controlled study for 48 weeks showed...
a marginally significant improvement in 6MWT for those receiving low-dose (40 mg/kg/d) ataluren only; those on high-dose (80 mg/kg/d) treatment did not improve in their 6MWT when compared with placebo, and the results were attributed to ataluren’s bell-shaped dose–response curve. Ataluren has received conditional approval by the European Medicines Agency since August 2014; results from the confirmatory trial (NCT02099059) is currently pending. Clinical trials involving other nonsense mutation suppression agents including arbekacin sulfate (NCT01918384) are being planned.

**Cell therapy using muscle precursor cells or stem cells**

Earlier attempts with myoblasts transfer were unsuccessful due to a number of factors, including limited viability of the donor cells after transplantation and suboptimal response from the use of older immunosuppressive regimen. Even though a recent clinical trial showed that intra-arterial transplantation of human leukocyte antigen-matched sibling donor mesoangioblasts with better immunosuppression therapy was relatively safe and well tolerated, only a low level of donor DNA was found in the muscle biopsies, and no functional improvements were seen among the five boys with DMD posttransplant. New cell therapies including induced pluripotent stem cells offer the potential of yielding an unlimited supply of autologous stem cells; however, patient-derived induced pluripotent stem cells will need to be genetically corrected before transplantation, and the long-term safety of this approach remains undefined.

**Membrane stabilization and upregulation of cytoskeletal proteins**

Compensatory upregulation of cytoskeleton proteins including utrophin, alpha-7-beta-1 integrin, biglycan, and sarcospan has been shown to stabilize the sarcolemma, in the absence of dystrophin in mdx mice, with improvement seen in the muscle biopsies. SMT C1100 is an oral bioavailable molecule specifically designed to target the utrophin-A promoter to increase utrophin expression; both SMT C1100 and its related compounds SMT022357 were shown in vitro and in vivo experiments to increase the production of utrophin and reduce the dystrophic changes in the skeletal and cardiac muscles. Further clinical trials data related to SMT C1100 (NCT02056808 and NCT02383511) are currently pending.

**Treatment of secondary cascades**

**Anti-inflammatory drugs**

The IκB kinase/nuclear factor-kappa B (NF-κB) signaling is persistently elevated in immune cells and regenerative muscle fibers in both animal models and patients with DMD. As well, activators of NF-κB such as tumor necrosis factor-α and interleukins 1 and 6 are upregulated in DMD muscles. Pharmacological inhibition of NF-κB using the NEMO-binding domain peptide resulted in improved pathology and muscle function in mouse models of muscular dystrophy. Additional research is needed to identify the role of selective NF-κB modulators and similar anti-inflammatory interventions for DMD.

Other potential anti-inflammatory therapies including N-acetylcysteine, green tea extract, idebenone, melatonin, and pentoxifylline were previously tried for DMD, with inconclusive results. Newer agents including givinostat (NCT01761292), a histone deacetylase inhibitor; CAT1004 (NCT02439216), an oral molecule that inhibits activated NF-κB; and flavocoxid (NCT01335295), a blend of plant-derived flavonoids with anti-inflammatory activity, are currently under evaluation as potential disease-modifying treatment for DMD.

**Antifibrotic drugs**

Elevated levels of TGF-β in muscular dystrophies stimulate fibrosis and impair muscle regeneration by blocking the activation of satellite cells. A number of antifibrotic agents have been tested in murine models of muscular dystrophy, including losartan, an angiotensin II-type 1 receptor blocker that reduces the expression of TGF-β. Other potential fibrosis inhibitors include HT-100 (halofuginone), FG-3019, a monoclonal antibody to connective tissue growth factor, and targeted microRNAs; further clinical trials are pending.

**Muscle regeneration**

Myostatin is a negative regulator of muscle mass. Inhibition or blockade of endogenous myostatin offers a potential means to compensate for the severe muscle wasting that is common in many types of muscular dystrophies including DMD. A Phase I/II multicenter clinical trial using MYO-029, a myostatin blocking antibody for adult subjects with Becker muscular dystrophies and other dystrophies, demonstrated safety, but the study was not sufficiently powered for efficacy. Clinical trials using follistatin and other myostatin inhibitors including PF-06252616 (NCT02310764) and BMS-986089 (NCT02515669) are currently under way. As well, the therapeutic potential of insulin growth factor (NCT01207908) as a positive regulator of muscle development and regeneration was shown in the dystrophic mouse models, especially when combined with mesenchymal stromal cells. Due to its...
regeneration-enhancing mechanism, this combinational approach may have general applicability for other muscular dystrophies.

Treatment of muscle ischemia
Loss of dystrophin leads to displacement of neuronal nitric oxide synthase and reduction of muscle-derived nitric oxide to the microvasculature, resulting in functional muscle ischemia and further muscle injury. Strategies to increase blood flow include pharmaceutical inhibition of either phosphodiesterase-5 or ACE, induction of angiogenesis through delivery of vascular endothelial growth factor (VEGF), or downregulation of the VEGF decoy-receptor type 1 (VEGFR-1 or Flt-1). Despite initial promising results, clinical trials involving the use of tadalafil as disease-modifying treatment for DMD (NCT01865084 and 0170511) have recently been terminated due to a lack of demonstrated efficacy in slowing the decline of the 6MWT.

Future therapeutic targets
Given the limited success of exon skipping and other disease-modifying treatment for DMD to date, future clinical trials may include pharmacogenomics consideration, high-throughput screening, mRNA or genome-wide association studies, and additional translational research from animal models to identify other potential therapeutic options. Current challenges including T-cell-mediated immune response or antibodies to generated dystrophin, limited evidence of dystrophin production in muscle biopsies, inefficient methods of drug delivery to the whole body, and inconsistent efficacy will need to be resolved. The long-term safety and tolerability of ataluren, eplepsone, and drisapersen will await additional monitoring and further Food and Drug Administration review. Currently, all three treatments have not been formally approved by the Food and Drug Administration due to insufficient data on long-term efficacy. Patient-focused perspective including health-related quality of life, satisfaction with care, acceptability or adherence to treatment, and participation in clinical trials will need to be considered in further collaborative research among neuromuscular disease registries and academic centers.

Correction of the genetic defect using engineered nucleases holds promise for the treatment of DMD. Recent studies on mdx mouse showed functional recovery in treated mice with RNA-guided clustered regularly interspaced short palindromic repeats-Cas9 endonucleases delivered by adeno-associated virus, with reversal of dystrophic changes in skeletal muscle fibers and cardiomyocytes, as well as in muscle satellite cells. The same genome editing technology can potentially benefit the majority of individuals with DMD, especially when combined with newborn screening. As well, a new clinical trial involving the study of VBP15, an oral glucocorticoid analog with anti-inflammatory properties and improved side-effect profile, is scheduled to begin later this year for ambulatory boys with DMD.

Conclusion
The pathogenesis affecting DMD is complex; multiple interventions targeting different disease processes are needed. Early recognition and precise genetic diagnosis will allow for individualized therapeutic options for DMD. Even though there is presently no cure, respiratory intervention and other supportive strategies as outlined in the current standard of care for DMD have led to improved survival and better health-related quality of life for many affected individuals. New emerging treatments will depend on the appropriate use of clinical end points and sensitive surrogate outcome measures such as muscle MRI and circulating biomarkers to detect meaningful changes in disease progression.

Disclosure
The author reports no conflicts of interest in this work.

References


Neuropsychiatric Disease and Treatment

Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the ‘PsychINFO’ database and CAS, and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.